Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 07.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | mplated thereby. As a result, and as disclosed in Item 5.02, the New Sponsor replaced the Company’s current directors an |
Stammdaten
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
Unternehmen & Branche
| Name | Tevogen Bio Holdings Inc. |
|---|---|
| Ticker | TVGN |
| CIK | 0001860871 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 27,3 Mio. USD |
| Beta | -0,30 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -26,275,432 | -8.08 | 4,382,994 | -8,234,726 | |
| 2025-09-30 | 10-Q | -5,726,812 | -0.03 | 4,493,669 | -7,823,896 | |
| 2025-06-30 | 10-Q | -5,503,979 | -0.03 | 4,269,136 | -9,484,742 | |
| 2025-03-31 | 10-Q | -10,367,061 | -0.07 | 4,073,178 | -7,720,096 | |
| 2024-12-31 | 10-K | -13,727,380 | -3.50 | 3,461,675 | -6,674,005 | |
| 2024-09-30 | 10-Q | -5,884,223 | -0.03 | 4,289,472 | -6,190,469 | |
| 2024-06-30 | 10-Q | -9,663,447 | -0.04 | 3,310,259 | -7,663,897 | |
| 2024-03-31 | 10-Q | 11,264,842 | -0.26 | 3,363,407 | -5,802,670 | |
| 2023-12-31 | 10-K | -60,477,680 | -2.44 | 5,505,503 | -94,428,897 | |
| 2023-09-30 | 10-Q | -3,904,951 | -0.03 | 26,409,887 | -90,796,665 | |
| 2023-06-30 | 10-Q | -22,184,353 | -0.18 | 26,375,265 | -86,891,714 | |
| 2023-03-31 | 10-Q | -30,756,144 | -0.26 | 25,470,477 | -64,707,361 | |
| 2022-12-31 | 10-K | 4,408,361 | 357,138,356 | -33,951,217 | ||
| 2022-09-30 | 10-Q | 1,612,864 | 354,542,198 | -14,657,560 | ||
| 2022-06-30 | 10-Q | 206,998 | 352,979,285 | -14,046,699 | ||
| 2022-03-31 | 10-Q | -25,988 | 0.00 | 352,829,802 | -14,253,697 | |
| 2021-12-31 | 10-K | -28,745 | 352,852,166 | -14,227,709 | ||
| 2021-09-30 | 10-Q | -115 | 166,789 | 13,586 | ||
| 2021-06-30 | 10-Q | -11,299 | 13,701 | |||
| 2021-04-30 | 10-Q | -6,983 | 18,017 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.